by GlobeNewsWire | Apr 1, 2016 | Globe Newswire
MENLO PARK, Calif., April 01, 2016 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...
by GlobeNewsWire | Mar 21, 2016 | Globe Newswire
In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines over Long-Term Extension Study Conference Call and Webcast with Slides to Be Held Today at...
by GlobeNewsWire | Mar 21, 2016 | Globe Newswire
– Company Receives Final FDA Confirmation to Initiate Phase 3 Studies Using Next Generation INOpulse Device – – Management to Host a Conference Call Today at 8:30 a.m. ET – WARREN, N.J., March 21, 2016 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc....
by GlobeNewsWire | Mar 2, 2016 | Globe Newswire
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March 02, 2016 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc....
by GlobeNewsWire | Dec 16, 2015 | Globe Newswire
MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...